Search Results - "Eid, Marc"

Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) –based regimens by Eid, Marc, Labaki, Chris, Semaan, Karl, Saliby, Renee Maria, Saad, Eddy, Shah, Valisha, Choueiri, Toni K.

“…4557 Background: ICI-based regimens (ICI + ICI or ICI + VEGF targeted therapy [VEGF-TT]) represent current standard of care systemic therapies for the…”
Get full text

Liquid biopsy in renal cell carcinoma by Machaalani, Marc, Eid, Marc, Semaan, Karl, El Hajj Chehade, Razane, Nawfal, Rashad, Baca, Sylvan C, Choueiri, Toni K

“…This commentary focuses on the article by Correa et al on the association of circulating tumor DNA with patient prognosis in renal cell carcinoma…”
Get full text

59 Risk Factors of Immune Related Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors by Chehade, Razane El Hajj, Semaan, Karl, Saliby, Renee Maria, Saad, Eddy, Nawfal, Rashad, Machaalani, Marc, Eid, Marc, Yekeduz, Emre, Steiner, Clara, Sun, Maxine, Kaymakcalan, Marina, Choueiri, Toni K

“…Abstract Background Immune checkpoint inhibitor (ICI) based combinations have become the standard of care for first-line treatment in patients with metastatic…”
Get full text

Applying genomic analysis to refine unclassified renal cell carcinoma by Yekeduz, Emre, Braun, David A., El Hajj Chehade, Razane, Eid, Marc, Labaki, Chris, Machaalani, Marc, Nassar, Amin, Nawfal, Rashad, Saad, Eddy, Saliby, Renee Maria, Semaan, Karl, Sun, Maxine, Hirsch, Michelle S., Ürün, Yüksel, El Zarif, Talal, CHOUEIRI, Toni K.

“…4551 Background: Despite the improvements in genomic and pathological techniques to identify renal cell carcinoma (RCC), 2-6% of all patients with RCC cannot…”
Get full text

ERBB2 mutations and association with molecular phenotype in urothelial carcinoma by Machaalani, Marc, El Zarif, Talal, Stockhammer, Paul, Semaan, Karl, Eid, Marc, El Hajj Chehade, Razane, Nawfal, Rashad, Yekeduz, Emre, Nassar, Amin, Lee, Gwo-Shu Mary, Baca, Sylvan C., CHOUEIRI, Toni K., Grant, Michael J, Bellmunt, Joaquim

“…4590 Background: Activating mutations (mut) in ERBB2 are present in up to 11% of urothelial carcinoma (UC). ERBB2 -targeted therapies have demonstrated…”
Get full text

Detection of neuroendocrine prostate cancer through plasma-based epigenomic profiling by Eid, Marc, Semaan, Karl, Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Lakshminarayanan, Gitanjali, El Zarif, Talal, Savignano, Hunter, Canniff, John, Saliby, Renee Maria, Saad, Eddy, Pomerantz, Mark, Baca, Sylvan, Freedman, Matthew, Berchuck, Jacob E, Choueiri, Toni K.

“…201 Background: Neuroendocrine prostate cancer (NEPC) is an aggressive resistance phenotype that can develop in men with metastatic prostate adenocarcinoma…”
Get full text

24 Applying genomic analysis to refine unclassified renal cell carcinoma by Yekeduz, Emre, Braun, David A, Chehade, Razane El Hajj, Eid, Marc, Labaki, Chris, Machaalani, Marc, Nassar, Amin, Nawfal, Rashad, Saad, Eddy, Saliby, Renee Maria, Semaan, Karl, Sun, Maxine, Hirsch, Michelle S, Ürün, Yüksel, Zarif, Talal El, Choueiri, Toni K

“…Abstract Background Despite the improvements in genomic and pathological techniques to identify renal cell carcinoma (RCC), 2-6% of all patients with RCC…”
Get full text

49 Inhibition of AXL along with c-Met potentially halts resistance development in renal cell carcinoma by Machaalani, Marc, Sabarwal, Akash, Rawat, Laxminarayan, Balan, Murugabaskar, Eid, Marc, Saad, Eddy, Semaan, Karl, Yang, Yifan, Ascione, Josie, Freedman, Matthew, Lee, Gwo-Shu Mary, Pal, Soumitro, Choueiri, Toni K

“…Abstract Background c-Met, a receptor tyrosine kinase (RTK), is overexpressed in renal cell carcinoma (RCC) and correlates with a decreased survival rate. Upon…”
Get full text

Association of enfortumab vedotin (EV) toxicity with baseline parameters and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) by Semaan, Karl, El Zarif, Talal, Saliby, Renee Maria, Eid, Marc, Saad, Eddy, Labaki, Chris, Kwak, Lucia, Kaymakcalan, Marina D., Baca, Sylvan, Berg, Stephanie A., Xie, Wanling, Mantia, Charlene, Choueiri, Toni K., McGregor, Bradley Alexander, Bellmunt, Joaquim

“…e16585 Background: EV is an antibody-drug conjugate approved for the treatment of mUC. Toxicities of special interest with EV are neuropathy, rash, and…”
Get full text

Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC) by Saad, Eddy, Labaki, Chris, Saliby, Renée-Maria, Bakouny, Ziad, Song, Li, Wall, McKenzy, Pan, Wenting, Semaan, Karl, Eid, Marc, Gwo-Shu, Mary Lee, Braun, David, Liu, Xiaole Shirley, Choueiri, Toni

“…Abstract Background Treatment options for mRCC have evolved to include VEGF targeted therapies (VEGF-TT), immune checkpoint inhibitors (ICIs), or combinations…”
Get full text

International medical graduates (IMG) representation at international oncology conference meetings by Roy, Arya Mariam, Bakouny, Ziad, Dizman, Nazli, Ozay, Zeynep Irem, Mohan Lal, Bhavesh, Nawfal, Rashad, Eid, Marc, El Hajj Chehade, Razane, Machaalani, Marc, Butt, Ayesha, Aggarwal, Charu, Bekaii-Saab, Tanios S., Chavez-MacGregor, Mariana, Lopes, Gilberto, Marshall, Ariela Lucy, Murphy, Martina Cathryn, Owonikoko, Taofeek K., Lee, Alfred Ian, CHOUEIRI, Toni K.

“…9000 Background: Despite IMGs accounting for up to one-third of all practicing oncologists in the United States, little is known about their contributions to…”
Get full text

Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation by Semaan, Karl, El Zarif, Talal, Seo, Ji-Heui, Eid, Marc, Canniff, John, Fortunato, Brad, Savignano, Hunter, Davidsohn, Matthew P., Lakshminarayanan, Gitanjali, Saad, Eddy, Saliby, Renee Maria, Bakouny, Ziad, Matar, Sayed, Nuzzo, Pier Vitale, Berchuck, Jacob E, Signoretti, Sabina, Braun, David A., Freedman, Matthew, Baca, Sylvan, Choueiri, Toni K.

“…449 Background: Sarcomatoid differentiation (SD) in renal cell carcinoma (RCC) is associated with poor survival and heightened response to immune checkpoint…”
Get full text

Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study by Saliby, Renee Maria, Xie, Wanling, Wells, J Connor, Saad, Eddy, Eid, Marc, Labaki, Chris, Semaan, Karl, Ferrier, Evan, Lemelin, Audreylie, Suárez, Cristina, Ruiz-Morales, Jose Manuel, Powles, Thomas, Wood, Lori, Ebrahimi, Hedyeh, de Velasco, Guillermo, Takemura, Kosuke null, Agarwal, Neeraj, Braun, David A., Heng, Daniel Yick Chin, Choueiri, Toni K.

“…400 Background: In Ph3 trials, assessment for primary endpoint of OS necessitates extended follow-up (f/u) periods, larger pool of events, and higher…”
Get full text

Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma by Saad, Eddy, Labaki, Chris, Miron, Benjamin, Park, Jihye, Bakouny, Ziad, Nassar, Amin, Saliby, Renee Maria, Semaan, Karl, Eid, Marc, Meli, Kevin, Nabil Laimon, Yasmin, Geynisman, Daniel M., Kokate, Rutika, Braun, David A., Signoretti, Sabina, McGregor, Bradley Alexander, Plimack, Elizabeth R., Choueiri, Toni K., Van Allen, Eliezer Mendel, Zibelman, Matthew R.

“…459 Background: While immune checkpoint inhibitors (ICI) have improved outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC), acquired…”
Get full text

22 Association of a germline single nucleotide polymorphism (SNP) in the interleukin-7 (IL7) gene with immune-related adverse events (irAEs) by Saad, Eddy, Mehrabad, Elnaz Mirazei, Labaki, Chris, Saliby, Renée Maria, Semaan, Karl, Eid, Marc, Machaalani, Marc, Chehade, Razane El Hajj, Nawfal, Rashad, Sun, Maxine, Sharon, Elad, Shah, Parantu, Vemula, Sai Vikram, Gupta, Saurabh, Braun, David, Van Allen, Eliezer, Gusev, Alexander, Choueiri, Toni

“…Abstract Background Adverse events (AEs) can limit treatment immune checkpoint inhibitors (ICI) efficacy and worsen patient outcomes. Our group recently…”
Get full text

20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study by Saliby, Renee Maria, Xie, Wanling, Wells, Connor J, Saad, Eddy, Eid, Marc, Semaan, Karl, Labaki, Chris, Ferrier, Evan, Zarba, Martin, Ebrahimi, Hedyeh, Ravi, Praful, Suarez, Cristina, Morales, Jose Ruiz, McKay, Rana R, Powles, Thomas, Wood, Lori, Lalani, Aly-Khan A, Pal, Sumanta K, de Velasco, Guillermo, Takemura, Kosuke, Agarwal, Neeraj, Braun, David A, Heng, Daniel Y, Choueiri, Toni K

“…Abstract Background In Phase 3 trials, the assessment for primary endpoint of overall survival (OS) necessitates extended follow-up periods, a larger pool of…”
Get full text

46 Radiological tumor burden is an independent risk factor for survival in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with first line immunotherapy (IO)-based regimens by Nawfal, Rashad, Eid, Marc, Semaan, Karl, Paul, Morgan A, Saliby, Renee Maria, Chehade, Razane El Hajj, Machaalani, Marc, Phillips, Noa, Canniff, John, Saad, Eddy, Vasseur, Damien, Zarif, Talal El, Yekeduz, Emre, Sun, Maxine, Baca, Sylvan C, Braun, David, Xie, Wanling, Krajewski, Katherine, Choueiri, Toni

“…Abstract Background IO-based regimens (IO + IO or IO + VEGF inhibitor) represent current standard of care systemic therapies for the management of patients…”
Get full text

44 Liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma by Semaan, Karl, Zarif, Talal El, Eid, Marc, Canniff, John, Phillips, Noa, Fortunato, Bard, Savignano, Hunter, Davidson, Matthew P, Chehade, Razane Hajj, Garinet, Simon, Saad, Eddy, Saliby, Renee Maria, Sun, Maxine, Seo, Ji-Heui, Berchuck, Jacob E, Braun, David, Freedman, Matthew L, Choueiri, Toni K, Baca, Sylvan C

“…Abstract Background Sarcomatoid differentiation (SD) in renal cell carcinoma (RCC) is associated with poor survival and heightened response to immune…”
Get full text

Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma by Labaki, Chris, Saliby, Renee Maria, Bakouny, Ziad, Saad, Eddy, Semaan, Karl, Eid, Marc, Lalani, Aly-Khan, Choueiri, Toni K., Braun, David A.

“…Patients with metastatic clear cell renal cell carcinoma (mccRCC) experience highly heterogeneous outcomes when treated with standard-of-care systemic…”
Get full text

Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy by Ali, Muhammad, Eid, Marc, Saliby, Renee Maria, Choi, Sharon, McKay, Rana R, Siva, Shankar, Braun, David A, Chen, Yu-Wei

“…The management of renal cell carcinoma (RCC) has advanced significantly in the past two decades. Many promising functional imaging modalities such as…”
Get more information